Aveanna Healthcare Holdings Inc. (AVAH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 30/100 (MEDIUM), 133.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.91% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Are Investors Undervaluing Aveanna Healthcare (AVAH) Right Now?
- Jim Cramer Compares Aveanna Healthcare (AVAH) With Hinge Health (HNGE)
- Here's Why Aveanna Healthcare (AVAH) is a Great Momentum Stock to Buy
- Aveanna Healthcare Holdings Inc. (AVAH) Hits Fresh High: Is There Still Room to Run?
- Aveanna Healthcare Holdings (AVAH) Looks Undervalued On Paper, Is The Earnings Outlook Enough?
- Aveanna Healthcare Holdings (AVAH) Stock Sees Fair Value Lift After Q2 And Analyst Revisions
- Aveanna (AVAH) Stock Looks Reasonable On Its Very Large Three Year Run
- Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna Healthcare
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Aveanna Healthcare Holdings Inc..
Full AVAH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.